#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Christopher Rold Email
VP, Vector Development and QC . Adicet Bio
Menlo Park, CA
LocationPrimary Email
How to contact Christopher Rold
Join and see Christopher's contact info for free!Phone
Current Roles
Employees:
170Revenue:
$42.7MAbout
Adicet Bio, Inc. is a privately held, pre-clinical stage biotechnology company engaged in the design and development of cutting-edge immunotherapies with initial focus on cancer. Adicet is developing novel universal immune cell therapies based on gamma delta T cells engineered with Chimeric Antigen Receptors (CARs) or T Cell Receptors (TCRs). Adicet is also focused on identifying and validating cancer specific targets directed to the intracellular proteome and generating TCR-like MAbs (TCRLs) directed to these cancer-specific peptide targets presented by MHC Class I complexes. These TCRLs can be used to arm T cells, as T cell engagers or as Antibody Drug Conjugates (ADC). In August 2016, Adicet entered a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop next-generation engineered immune-cell therapeutics using Adicet's gamma delta T cell allogeneic platform technology. Adicet Bio raised $51M in series A financing led by OrbiMed Partners, OrbiMed Israel, Novartis Venture Fund and Pontifax.Adicet Bio Address
1000 Bridge ParkwayMenlo Park, CA
United States